Freenome Q3 2026 Results: Turns Profitable, Net Income $60.1M
Freenome, Inc. completed a business combination with Perceptive Capital Solutions Corp. on July 20, 2026, and is currently focused on developing blood-based screening tests like SimpleScreen CRC and SimpleScreen Lung. The company reports significant ongoing net losses and anticipates the need for additional capital to fund operations and commercialization efforts.
- Key figure
- Net income $60.1M